0

Insulin-like-growth-factor-binding-protein-3 (IGFBP-3) Contrasts Melanoma Progression in Vitro and in Vivo

Antimo Naspi, Vincenzo Panasiti, Franco Abbate, Vincenzo Roberti, Valeria Devirgiliis, Michela Curzio, Martina Borghi, Francesco Lozupone, Simone Carotti, Sergio Morini, Eugenio Gaudio, Stefano Calvieri, etc.

PLoS One. 2014 Jun 6;9(6):e98641.

PMID: 24905466

Abstract:

Insulin-like-factor-binding-protein 3 (IGFBP-3) is known to modulate the activity of insulin-like growth factors (IGFs) besides having a number of IGF-independent effects on cell growth and survival. IGFBP-3 has been reported to decrease significantly in the blood serum of patients affected by certain cancers. In the present work, we have evaluated the levels of IGFBP-3 in the blood serum and tissues of patients affected by cutaneous melanoma, showing that loss of IGFBP-3 from both is strongly correlated with disease progression and reduced survival. In vitro treatment with IGFBP-3 of human and murine metastatic melanoma cell lines specifically inhibited the cells' migratory and invasive behaviour, inducing up-regulation of melanocytic differentiation markers such as tyrosinase activity and melanin content. A molecular analysis of the cellular pathways transducing the effect of IGFBP-3 implicated the Akt-GSK3β axis. Moreover, administration of IGFBP-3 in vivo to SCID mice inoculated with human metastatic melanoma cells strongly reduced or completely inhibited tumor growth. In summary, IGFBP-3 appears to exert a specific inhibitory effect on melanoma growth and dissemination, suggesting that it may qualify as a useful therapeutic agent in melanomas and perhaps other cancers, at the least as a valid adjuvant therapy during treatment with conventional anti-tumoral drugs.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
IAR42413300 Insulin-Like Growth Factor Binding Protein-3 human Insulin-Like Growth Factor Binding Protein-3 human Price
qrcode